Cargando…

Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases

Extraskeletal myxoid chondrosarcoma (EMCS) is an undifferentiated mesenchymal malignancy; however, its immune microenvironment remains to be elucidated. The case of a 34‐year‐old woman who developed EMCS metastasizing to the pleura is presented here. The pleural EMCS showed hypervascularity, absent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Ryosuke, Soda, Hiroshi, Senju, Hiroaki, Fujioka, Masaki, Shimada, Midori, Yamashita, Koki, Irifune, Satoshi, Tagawa, Ryuta, Dotsu, Yosuke, Iwasaki, Keisuke, Taniguchi, Hirokazu, Takemoto, Shinnosuke, Fukuda, Yuichi, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527174/
https://www.ncbi.nlm.nih.gov/pubmed/35974707
http://dx.doi.org/10.1111/1759-7714.14613
_version_ 1784801026767847424
author Ogata, Ryosuke
Soda, Hiroshi
Senju, Hiroaki
Fujioka, Masaki
Shimada, Midori
Yamashita, Koki
Irifune, Satoshi
Tagawa, Ryuta
Dotsu, Yosuke
Iwasaki, Keisuke
Taniguchi, Hirokazu
Takemoto, Shinnosuke
Fukuda, Yuichi
Mukae, Hiroshi
author_facet Ogata, Ryosuke
Soda, Hiroshi
Senju, Hiroaki
Fujioka, Masaki
Shimada, Midori
Yamashita, Koki
Irifune, Satoshi
Tagawa, Ryuta
Dotsu, Yosuke
Iwasaki, Keisuke
Taniguchi, Hirokazu
Takemoto, Shinnosuke
Fukuda, Yuichi
Mukae, Hiroshi
author_sort Ogata, Ryosuke
collection PubMed
description Extraskeletal myxoid chondrosarcoma (EMCS) is an undifferentiated mesenchymal malignancy; however, its immune microenvironment remains to be elucidated. The case of a 34‐year‐old woman who developed EMCS metastasizing to the pleura is presented here. The pleural EMCS showed hypervascularity, absent PD‐L1 expression, and a lack of tumor mutational burden and pathogenic variants. Immunohistological examination of the pleural lesions showed predominant M2 macrophages and sparse CD8(+) T cells. EMCS and the tumor stroma were positive for transforming growth factor‐β1 (TGF‐β1) and vascular endothelial growth factor (VEGF). In contrast, a small number of the stromal vessels were positive for hypoxia inducible factor‐1α (HIF‐1α). TGF‐β1 and VEGF in the tumor stroma and low antigenicity of the tumor cells may help explain how EMCS induced the immunosuppressive microenvironment. These findings may encourage investigators to explore novel combined immunotherapy for EMCS, such as TGF‐β1 and VEGF inhibitors, and specific therapy for enhancing tumor antigens.
format Online
Article
Text
id pubmed-9527174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-95271742022-10-06 Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases Ogata, Ryosuke Soda, Hiroshi Senju, Hiroaki Fujioka, Masaki Shimada, Midori Yamashita, Koki Irifune, Satoshi Tagawa, Ryuta Dotsu, Yosuke Iwasaki, Keisuke Taniguchi, Hirokazu Takemoto, Shinnosuke Fukuda, Yuichi Mukae, Hiroshi Thorac Cancer Case Reports Extraskeletal myxoid chondrosarcoma (EMCS) is an undifferentiated mesenchymal malignancy; however, its immune microenvironment remains to be elucidated. The case of a 34‐year‐old woman who developed EMCS metastasizing to the pleura is presented here. The pleural EMCS showed hypervascularity, absent PD‐L1 expression, and a lack of tumor mutational burden and pathogenic variants. Immunohistological examination of the pleural lesions showed predominant M2 macrophages and sparse CD8(+) T cells. EMCS and the tumor stroma were positive for transforming growth factor‐β1 (TGF‐β1) and vascular endothelial growth factor (VEGF). In contrast, a small number of the stromal vessels were positive for hypoxia inducible factor‐1α (HIF‐1α). TGF‐β1 and VEGF in the tumor stroma and low antigenicity of the tumor cells may help explain how EMCS induced the immunosuppressive microenvironment. These findings may encourage investigators to explore novel combined immunotherapy for EMCS, such as TGF‐β1 and VEGF inhibitors, and specific therapy for enhancing tumor antigens. John Wiley & Sons Australia, Ltd 2022-08-16 2022-10 /pmc/articles/PMC9527174/ /pubmed/35974707 http://dx.doi.org/10.1111/1759-7714.14613 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Ogata, Ryosuke
Soda, Hiroshi
Senju, Hiroaki
Fujioka, Masaki
Shimada, Midori
Yamashita, Koki
Irifune, Satoshi
Tagawa, Ryuta
Dotsu, Yosuke
Iwasaki, Keisuke
Taniguchi, Hirokazu
Takemoto, Shinnosuke
Fukuda, Yuichi
Mukae, Hiroshi
Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
title Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
title_full Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
title_fullStr Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
title_full_unstemmed Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
title_short Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
title_sort immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: a case of pleural metastases
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527174/
https://www.ncbi.nlm.nih.gov/pubmed/35974707
http://dx.doi.org/10.1111/1759-7714.14613
work_keys_str_mv AT ogataryosuke immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT sodahiroshi immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT senjuhiroaki immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT fujiokamasaki immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT shimadamidori immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT yamashitakoki immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT irifunesatoshi immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT tagawaryuta immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT dotsuyosuke immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT iwasakikeisuke immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT taniguchihirokazu immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT takemotoshinnosuke immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT fukudayuichi immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases
AT mukaehiroshi immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases